Switching algorithms: from one immunomodulatory agent to another
Author:
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Link
http://link.springer.com/content/pdf/10.1007/s00415-008-1007-3.pdf
Reference16 articles.
1. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O (2006) Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 13:471–474
2. Carrá A, Onaha P, Luetic G, Burgos M, Crespo C, Deri N, Halfon J, Jacks G, Lopez A, Sinay V, Vrech C (2006) Switching of therapies in Argentina: 2-year follow-up. Mult Scler 12(Suppl 1):S94–S96
3. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H (2004) Identifying and treating patients with suboptimal responses. Neurology 63:S33–S40
4. Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M (2007) Randomized, double-blind, dosecomparison study of glatiramer acetate in relapsing-remitting MS. Neurology 68:939–944
5. Gajofatto A, High A, Waubant E (2007) Switching disease-modifying therapy (DMT) after treatment failure: does it have an impact on the course of relapsing-remitting multiple sclerosis (RRMS). Neurology 68(Suppl 1):A239
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2021-03-18
2. Usage trend of oral drugs for multiple sclerosis patients in Argentina;Multiple Sclerosis and Related Disorders;2021-01
3. Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?;Journal of Clinical Neurology;2018
4. Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial;Therapeutic Advances in Neurological Disorders;2018-01
5. Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2—Surveillance for Treatment Complications and Disease Progression;American Journal of Neuroradiology;2017-04-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3